Prognoses for intermediate-risk prostate cancer (PCa) remain heterogeneous. Improved substratification could optimize treatment and monitoring strategies. The objective was to validate this subclassification in a radical prostatectomy (RP) series.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Between 2000 and 2011, 4038 patients who underwent RP for intermediate-risk PCa in seven French academic centers were included. Unfavorable intermediate-risk (UIR) PCa was defined as having a primary Gleason score of 4, ≥50% positive biopsy cores (PPBC), or more than one D'Amico intermediate-risk factor (i.e., cT2b, PSA 10-20, or Gleason score 7). Remaining PCa cases were classified as favorable. Main endpoints were pathologic results (pT stage, final Gleason score, surgical margin status), and oncologic outcomes were assessed according to PSA recurrence-free survival (PSA-RFS). Univariate and multivariate analyses were performed using the log-rank test and the Cox proportional hazards model.
Median follow-up was 48 months (95% CI = [45-49]). Patients with UIR had worse PSA-RFS (68.17 vs. 81.98% at 4 years, HR = 1.97, 95% CI = [1.71; 2.27], p < 0.0001) compared to those with a favorable disease. The need for adjuvant therapy was significantly greater for UIR patients (43.5 vs. 29.2%, p < 0.0001). In multivariate analysis, primary Gleason score of 4 (HR = 1.81, 95% CI = [1.55; 2.12], p < 0.0001) and PPBC ≥ 50% (HR = 1.26, 95% CI = [1.02; 1.56], p = 0.0286) were significant preoperative predictors for worse PSA-RFS.
This study highlights the heterogeneity of NCCN intermediate-risk patients and validates (in a large RP cohort) the previously proposed subclassification for this group. This classification can significantly predict both pathologic and oncologic outcomes. This easy-to-use stratification could help physicians' decision making. Prospective study and new tools as genomic tests and novel molecular-based approaches can improve this stratification in the future for patient counseling.
World journal of urology. 2016 Dec 16 [Epub ahead of print]
Jean Baptiste Beauval, Guillaume Ploussard, Bastien Cabarrou, Mathieu Roumiguié, Adil Ouzzane, Jérome Gas, Annabelle Goujon, Gautier Marcq, Romain Mathieu, Sébastien Vincendeau, Xavier Cathelineau, Pierre Mongiat-Artus, Laurent Salomon, Michel Soulié, Arnaud Méjean, Alexandre de La Taille, Morgan Rouprêt, François Rozet, Committee of Cancerology of the Association of French Urology
Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1, av J Pouilhès, 31059, Toulouse Cedex, France. ., Department of Urology, Clinique St Jean du Languedoc, Toulouse, France., Institut Claudius Regaud, IUCT-O, 31059, Toulouse, France., Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1, av J Pouilhès, 31059, Toulouse Cedex, France., Department of Urology, Andrology and Renal Transplantation, CHU Lille, Lille, France., Department of Urology, Institut Mutualiste Monsouris, Paris-Descartes University, Paris, France., Department of Urology, Andrology and Renal Transplantation, CHU Rennes, Rennes, France., Department of Urology, Andrology and Renal Transplantation Hôpital Saint-Louis, Paris-7 Denis Diderot University, Paris, France., Department of Urology, Andrology and Renal Transplantation, CHU Mondor, Créteil, France., Department of Urology and Renal transplantation, HEGP, Paris, France., Department of Urology, Andrology and Renal Transplantation, CHU La Pitié Salpétrière, Paris, France.